Abdulrazzak Zarifa

472 total citations
25 papers, 286 citations indexed

About

Abdulrazzak Zarifa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Abdulrazzak Zarifa has authored 25 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Abdulrazzak Zarifa's work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Abdulrazzak Zarifa is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Abdulrazzak Zarifa collaborates with scholars based in United States. Abdulrazzak Zarifa's co-authors include Aung Naing, Daniel D. Karp, Jordi Rodón, Mingxuan Xu, Funda Meric‐Bernstam, Siqing Fu, David S. Hong, Bettzy Stephen, Peter Kim and Juan Lopez‐Mattei and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Abdulrazzak Zarifa

22 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abdulrazzak Zarifa United States 8 128 106 88 54 54 25 286
Naóe Kinoshita Japan 10 87 0.7× 135 1.3× 36 0.4× 11 0.2× 88 1.6× 52 267
Daiki Kayano Japan 12 48 0.4× 135 1.3× 116 1.3× 32 0.6× 42 0.8× 37 370
Matthew W. Jackson United States 9 76 0.6× 97 0.9× 77 0.9× 15 0.3× 95 1.8× 30 325
Dhanapathi Halanaik India 10 89 0.7× 87 0.8× 26 0.3× 17 0.3× 83 1.5× 27 285
J. S. Lee South Korea 9 190 1.5× 163 1.5× 62 0.7× 27 0.5× 215 4.0× 17 392
José Francisco Juanmartiñena Fernández Spain 9 67 0.5× 291 2.7× 111 1.3× 62 1.1× 101 1.9× 20 393
Ruşen Coşar Türkiye 10 91 0.7× 65 0.6× 50 0.6× 16 0.3× 106 2.0× 41 297
Cormac Owens Ireland 12 107 0.8× 55 0.5× 94 1.1× 37 0.7× 117 2.2× 40 419
Giulia Santo Italy 10 112 0.9× 59 0.6× 19 0.2× 28 0.5× 76 1.4× 41 307

Countries citing papers authored by Abdulrazzak Zarifa

Since Specialization
Citations

This map shows the geographic impact of Abdulrazzak Zarifa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdulrazzak Zarifa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdulrazzak Zarifa more than expected).

Fields of papers citing papers by Abdulrazzak Zarifa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abdulrazzak Zarifa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdulrazzak Zarifa. The network helps show where Abdulrazzak Zarifa may publish in the future.

Co-authorship network of co-authors of Abdulrazzak Zarifa

This figure shows the co-authorship network connecting the top 25 collaborators of Abdulrazzak Zarifa. A scholar is included among the top collaborators of Abdulrazzak Zarifa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdulrazzak Zarifa. Abdulrazzak Zarifa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hajjar, Joud, Bettzy Stephen, Serdar A. Gurses, et al.. (2025). Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open. 10(8). 105518–105518. 1 indexed citations
2.
Gouda, Mohamed A., Bettzy Stephen, Yanyan Tian, et al.. (2024). A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. SHILAP Revista de lepidopterología. 7(4). 247–254. 2 indexed citations
3.
Zarifa, Abdulrazzak, et al.. (2024). The efficacy of immune checkpoint inhibitors as a part of multimodality treatment in soft tissue and bone sarcoma in an academic community setting.. Journal of Clinical Oncology. 42(16_suppl). e23564–e23564.
4.
5.
Ahmed, Jibran, Bettzy Stephen, Sarina A. Piha‐Paul, et al.. (2023). Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 130(3). 400–409. 11 indexed citations
6.
Stephen, Bettzy, Joud Hajjar, Shrutii Sarda, et al.. (2023). T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. Journal for ImmunoTherapy of Cancer. 11(8). e007236–e007236. 9 indexed citations
7.
Thirumurthi, Selvi, Melissa W. Taggart, Bülent Yılmaz, et al.. (2022). Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. SHILAP Revista de lepidopterología. 5(2). 32–36. 5 indexed citations
8.
Hajjar, Joud, Tito R. Mendoza, Liangliang Zhang, et al.. (2021). Associations between the gut microbiome and fatigue in cancer patients. Scientific Reports. 11(1). 5847–5847. 29 indexed citations
9.
Alshawa, Anas, Alexandra P. Cadena, Bettzy Stephen, et al.. (2021). Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial. Investigational New Drugs. 39(4). 1113–1122. 4 indexed citations
10.
Zarifa, Abdulrazzak, Juan Lopez‐Mattei, Nicolas L. Palaskas, et al.. (2021). Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Advances in experimental medicine and biology. 1342. 377–387. 4 indexed citations
11.
Dev, Rony, Linda L. D. Zhong, Abdulrazzak Zarifa, et al.. (2021). Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Investigational New Drugs. 40(1). 124–133. 4 indexed citations
12.
Thein, Kyaw Zin, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, et al.. (2021). Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study. Investigational New Drugs. 39(5). 1357–1365. 6 indexed citations
13.
Zarifa, Abdulrazzak, Juan Lopez‐Mattei, Nicolas L. Palaskas, et al.. (2020). Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. Advances in experimental medicine and biology. 1244. 277–285. 11 indexed citations
14.
Thein, Kyaw Zin, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, et al.. (2020). 554P Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Annals of Oncology. 31. S480–S480. 1 indexed citations
15.
Glitza, Isabella C., Sapna P. Patel, Abdulrazzak Zarifa, et al.. (2020). 1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience. Annals of Oncology. 31. S756–S756. 3 indexed citations
16.
Thein, Kyaw Zin, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, et al.. (2020). 565P Selinexor in combination with topotecan in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study. Annals of Oncology. 31. S486–S486. 1 indexed citations
17.
Frumovitz, Michael, Shannon N. Westin, Gloria Salvo, et al.. (2020). Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecologic Oncology. 158(3). 570–575. 49 indexed citations
18.
Habra, Mouhammed Amir, Bettzy Stephen, Matthew T. Campbell, et al.. (2019). Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. Journal for ImmunoTherapy of Cancer. 7(1). 253–253. 108 indexed citations
19.
Agha, Ali, Abdulrazzak Zarifa, Peter Kim, et al.. (2019). The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics. Methodist DeBakey Cardiovascular Journal. 15(4). 258–258. 3 indexed citations
20.
Zarifa, Abdulrazzak, Peter Kim, Susan C. Gilchrist, et al.. (2019). Expression of T-cell populations and molecular markers of human myocardium with checkpoint-induced myocarditis.. Journal of Clinical Oncology. 37(8_suppl). 79–79. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naóe Kinoshita Breakdown of academic impact, for papers by Daiki Kayano Breakdown of academic impact, for papers by Matthew W. Jackson Breakdown of academic impact, for papers by Dhanapathi Halanaik Breakdown of academic impact, for papers by J. S. Lee Breakdown of academic impact, for papers by José Francisco Juanmartiñena Fernández Breakdown of academic impact, for papers by Ruşen Coşar Breakdown of academic impact, for papers by Cormac Owens Breakdown of academic impact, for papers by Giulia Santo
Rankless by CCL
2026